<DOC>
	<DOCNO>NCT01697293</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose triciribine phosphate give together paclitaxel , doxorubicin hydrochloride , cyclophosphamide see well work treat patient stage IIB-IV breast cancer . Triciribine phosphate may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , paclitaxel , doxorubicin hydrochloride , cyclophosphamide , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving triciribine phosphate paclitaxel , doxorubicin hydrochloride , cyclophosphamide may better treatment breast cancer .</brief_summary>
	<brief_title>Triciribine Phosphate , Paclitaxel , Doxorubicin Hydrochloride , Cyclophosphamide Treating Patients With Stage IIB-IV Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine recommended phase II dose PTX-200 ( triciribine phosphate ) give day 1 , 8 , 15 every 28 day ( maximum 9 dos ) combine weekly paclitaxel ( 80 mg/m^2 ) 12 week patient metastatic breast cancer . ( Phase I Expansion Cohort ) II . To determine pathologic response rate ( Residual Cancer Burden [ RCB ] score 0-1 ) sequential weekly paclitaxel plus PTX 200 weekly , 3 week 4 , follow doxorubicin ( doxorubicin hydrochloride ) ( 60 mg/m^2 ) cyclophosphamide ( 600 mg/m^2 ) every 2 week x 4 cycle patient clinical stage IIB-IIIC breast cancer . ( Phase II ) . III . To determine feasibility safety combination sequential weekly paclitaxel plus PTX-200 ( day 1 , 8 , 15 ) follow doxorubicin/cyclophosphamide . ( Phase II ) SECONDARY OBJECTIVES : I . To correlate pre-treatment level erb-b2 receptor tyrosine kinase ( ErbB ) 1 , 2 , 3 , 4 zinc finger protein 217 ( ZNF217 ) , phosphorylated level v-akt murine thymoma viral oncogene homolog 1 ( Akt ) , signal transducer activator transcription 3 ( acute-phase response factor ) ( STAT3 ) , extracellular signal-regulated protein kinases 1 2 ( Erk1/2 ) pathologic ( RCB score 0-1 ) response ( Sebti laboratory [ lab ] ) . ( Phase I II ) II . To correlate percent decrease level phosphorylated ( phospho- ) Akt ( S473 ) , phospho-S6 ( S235-236 ) , phospho-proline-rich Akt substrate , 40 kDa ( PRAS40 ) ( threonine [ Thr ] 246 ) , phosphatase tensin homolog ( PTEN ) , Stathmin , pyruvate dehydrogenase kinase , isozyme 1 ( PDK1 ) , cyclin D1 , phospho-STAT3 , ras homolog gene family , member C ( Rho C ) , phospho-Erk 1-2 pathologic response rate ( RCB score 0-1 ) , percent inhibition proliferation ( Ki-67 ) percent induction apoptosis ( terminal deoxynucleotidyl transferase dUTP nick end label [ Tunel ] ) ( Sebti lab ) . ( Phase I II ) OUTLINE : This phase I , dose-escalation study triciribine phosphate follow expansion cohort phase II study . COURSES A 1-12 ( PHASE I &amp; II ) : Patients receive triciribine phosphate intravenously ( IV ) 60 minute day 1 , 8 , 15 , 29 , 36 , 43 , 57 , 64 , 71 paclitaxel IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 79 . Treatment repeat every week 12 course absence disease progression unacceptable toxicity . COURSES B 1-4 ( PHASE II ) : Patients receive doxorubicin hydrochloride IV 5-10 minute cyclophosphamide IV 30-60 minute day 1 . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . SURGERY ( PHASE II ) : Eligible patient undergo modify radical mastectomy , radical mastectomy , segmental mastectomy lumpectomy axillary lymph node dissection biopsy . After completion study treatment , patient metastatic disease follow every 3 month 1 year patient locally advanced disease follow every 6 month 2 year yearly 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Phase I expansion cohort : Patients must histologically cytologically confirm adenocarcinoma breast associate clinical stage : IV ( see American Joint Committee Cancer [ AJCC ] stag criterion , 7th edition ) stage IIBIIIC ( expansion cohort ) Phase II : Patients must histologically cytologically confirm adenocarcinoma breast associate follow clinical stage : IIB , IIIA , IIIB , IIIC ( see AJCC stag criterion , 7th edition ) ; tumor must human epidermal growth factor receptor 2 ( Her2 ) /neu negative ( DAKO HercepTest , fluorescence base situ hybridization [ FISH ] , approve assay ) Phase I expansion cohort : Up two prior nontaxane chemotherapy regimens metastatic disease permit patient enrolled phase I portion trial ; patient HER2/neu positive breast cancer eligible ; patient treat prior anthracycline therapy neoadjuvant , adjuvant , metastatic therapy eligible unless follow condition meet : ( ) prior cumulative doxorubicin dose = &lt; 240 mg/m^2 ( epirubicin dose = &lt; 400 mg/m^2 ) , ( b ) leave ventricular ejection fraction ( LVEF ) obtain baseline least 50 % ( &gt; = 5 % low institutional limit normal whichever high ) ; patient estrogen receptor ( ER ) positive disease require relapse progression least one line endocrine therapy Phase II : No prior chemotherapy , irradiation , definitive therapeutic surgery ( e.g. , mastectomy lumpectomy axillary dissection ) malignancy ; patient prior sentinel lymph node biopsy malignancy eligible Patients receive tamoxifen another selective estrogen receptor modulator ( SERM ) prevention treatment breast cancer indication ( e.g. , osteoporosis , prior ductal carcinoma situ [ DCIS ] ) , receive aromatase inhibitor prevention treatment breast cancer , eligible ; patient hormonereceptor positive receive hormonal agent treatment breast cancer ( e.g. , Fulvestrant ) also eligible ; tamoxifen therapy hormonal agent discontinue least 1 week patient enrol study Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Leukocytes &gt; = 3,000/uL Absolute neutrophil count = &lt; 1,500/uL Platelets &gt; = 100,000/uL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) = &lt; 2.5 x institutional upper limit normal Left ventricular ejection fraction ( LVEF ) within normal institutional limit Creatinine within normal institutional limit LVEF institutional low limit normal ( &gt; = 50 % ) , least 5 % low limit normal prior anthracycline exposure ( echocardiogram nuclear scan within 12 week registration ) Electrocardiogram ( ECG ) correct QT ( QTC ) &lt; 450 msec Serum calcium within normal institutional limit Serum phosphorus within normal institutional limit Fasting glucose within normal limit Patients must diseasefree prior invasive malignancy &gt; = 2 year exception curativelytreated basal cell squamous cell carcinoma skin , carcinoma situ cervix ( phase II ) ; patient follow prior concurrent diagnosis eligible : lobular carcinoma situ , contralateral ductal carcinoma situ , contralateral invasive ductal and/or lobular cancer ( prior adjuvant chemotherapy previous breast malignancy ) Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients may receive investigational agent protocol therapy , 30 day prior begin protocol therapy ; least 1week interval last dose endocrine therapy protocol therapy , least 3 week last dose biologic therapy ( eg , bevacizumab ) cytotoxic therapy ( 2 week capecitabine weekly paclitaxel , 6 week mitomycinC nitrosoureas ) , adequately recovered adverse effect prior therapy meet eligibility criterion History allergic reaction attribute compound similar chemical biologic composition PTX200 agent use study ( e.g. , imidazole , quinolones ) Uncontrolled intercurrent illness include , limited , ongoing active infection , diabetes mellitus require therapy ( insulin oral hypoglycemic agent ) , congenital prolong QT syndrome , requirement drug know prolong QT interval , history QT prolongation , screen QTc &gt; = 450 msec , hypertriglyceridemia require therapy , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated PTX200 ; potential risk may also apply agent use study Human immunodeficiency virus ( HIV ) positive patient receive combination antiretroviral therapy exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>